Development and Validation of Stability-indicating HPLC Method for Betamethoasone Dipropionate and Related Substances in Topical Formulation

A new selective colorimetric method coupled with a high-resolution UV method for the consecutive quantification of three drugs in semi-solid preparations

Triderm® cream and ointment contain clotrimazole (CLO), betamethasone dipropionate (BET), and the poor UV absorbing gentamycin (GEN), in addition to the preservative benzyl alcohol (BEN) which exists only in a cream preparation. A green, selective colorimetric approach was elaborated to increase the sensitivity of GEN quantification in Triderm® preparations, which depends on the immediate formation of a pink ion-pair between GEN and erythrosine (ERY) reagent in an aqueous acidic medium. The ion pair was made soluble in water with the assistance of the surfactant agent poloxamer 188 which is presented in this manuscript as an efficient solubilizing agent for the hydrophobic ion-pair. This surfactant agent has the feature of not affecting the native color of ERY, additionally the ease of preparing its aqueous solution with no need for heating or long waiting. The resulting complex GEN-ERY was measured directly at 545nm. This colorimetric approach was coupled with the Unlimited Derivative Ratio (UDD), which is a new smart UV method employed for the concurrent quantification of BET and CLO in Triderm® preparations without any intervention from BEN, due to its capability to resolve an extremely overlapped ternary spectrum that has no extended part, iso-absorptive point or robust zero crossing point. The newly developed UDD method depends on filtrating and measuring the signal of BET and CLO through calculating the equality factor(F) for CLO and BET after dividing their spectrum by BEN spectrum, derivatizing the resulting ratio spectrum, then constructing a regression equation employing the F factor for each BET and CLO. The overlapping excipient BEN was quantified via the Double Divisor Ratio spectra derivative method (DDR) relying on using a divisor comprising of a mix of BET + CLO. The advanced spectrophotometric approach validity was checked by confirming the linearity, accuracy, precision, and specificity in accordance with the ICH directions. NO notable difference when statistically comparing the newly established approach to the reference approach.

Development and validation of a RP-UPLC method for the determination of betamethasone dipropionate impurities in topical formulations using a multivariate central composite design

The current study presents a specific, accurate, simple, and rapid UPLC method for the determination of impurities present in cream and ointment formulations of betamethasone dipropionate (BMD). The analytical method was optimized using central composite design (CCD) prior to the method validation. Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) were identified for the analytical method. A total of 17 experiments were carried out and verified the individual and interaction effects of CPPs. The CPPs were optimized using a numerical method by keeping the CQAs within the desired range (R1-R2: minimize & R3-R5: maximize) as an optimization goal. Optimized chromatographic separation was achieved using a Waters Acquity UPLC BEH C₁₈, 100 mm × 2.1 mm, 1.7 μm column with a gradient mode of elution comprising 20 mM phosphate buffer: ACN 70 : 30, v/v as mobile phase-A and 20 mM phosphate buffer: ACN 30 : 70, v/v as mobile phase-B. The developed method was validated in accordance with ICH guidelines. The validation data conclude that the developed method is specific, accurate, linear, precise, rugged, and robust for the quantification of impurities in BMD topical formulations.

Simultaneous Estimation of Apremilast and Betamethasone Dipropionate in Microsponge-Based Topical Formulation using a Stability Indicating RP-HPLC Method: A Quality-by-Design Approach

A stability-indicating reverse phase high-performance liquid chromatography method was developed and validated for simultaneous quantification of apremilast (APL) and betamethasone dipropionate (BD) in bulk as well as drug loaded microsponges. Various mobile phase systems were screened to check the system suitability followed by force degradation analysis to determine APL and BD stability under varying stress conditions. A central composite design model was used to optimize the column temperature and flow rate using Design Expert® (9.0.1). One factor at a time approach with five independent factors were used to validate the robustness of the method. Finally, APL and BD were precisely and accurately quantified from drug loaded microsponges using the validated method. A favorable separation of APL and BD was obtained on a Phenomenex® Luna C18 column using a mixture of 50 mM phosphate buffer containing 0.1% triethylamine (pH 6.1) and acetonitrile (60:40%v/v) as mobile phase. Both the drugs were found to be stable when exposed to stressors such as heat-, light-, alkali-, acid- and peroxide-induced degradation. The calibration curves were found to be linear with appreciable limit of detection and limit of quantification. Recovery and percentage relative standard deviation of peak areas for APL and BD were found to be < 2.0% and 99-100% in bulk drug solution and <2.0% and 99-103% in microsponge formulation, respectively. Statistical analysis using analysis of variance indicated that the model was significant (P < 0.001). Hence, the developed method can be effectively used to quantify APL and BD, both in bulk as well as microsponge formulations.

Stability of a Parenteral Formulation of Betamethasone and Levobupivacaine

Background: The therapeutic management of syndromes presenting simultaneously pain and inflammation often requires the administration of anesthetic and corticosteroid drugs by epidural administration. In this article, we studied a mixture that combines betamethasone and levobupivacaine, which demonstrates prolonged analgesic effects. To our knowledge, the stability of such a mixture in epidural solution has not been examined. Objective: To evaluate the chemical, physical, and microbiological stability of an extemporaneously prepared mixture. Methods: A solution of betamethasone acetate 1 mg/mL, betamethasone phosphate 1 mg/mL, and levobupivacaine hydrochloride 0.83 mg/mL was prepared in saline. The components were analyzed by high-performance liquid chromatography for up to 270 days of storage, protected and exposed to light, at room temperature, and stored in the refrigerator and at 45°C. In addition, sterility, organoleptic properties, and pH of the admixture were monitored. Results: There are no significant differences between drug concentrations obtained at room temperature and at refrigerated temperature. The accelerated conditions (45°C) demonstrated different results among the actives: betamethasone acetate and levobupivacaine hydrochloride are affected while betamethasone phosphate remains stable. The stability of the mixture does not depend on light exposure. The validity period of the different components in the mixture was estimated as 120 days for betamethasone phosphate and 163 days for levobupivacaine hydrochloride; betamethasone acetate remained unchanged during 155 days. Conclusion: Analgesic mixtures of betamethasone and levobupivacaine can be stored at ambient temperature in polypropylene vials for up to 120 days at the studied concentrations. These data enable the rationalization of the centralized preparation in the hospital pharmacy.